|1.||Besner, Gail E: 26 articles (07/2015 - 07/2002)|
|2.||Reilly, Raymond M: 20 articles (12/2015 - 12/2002)|
|3.||Higashiyama, Shigeki: 20 articles (10/2013 - 01/2002)|
|4.||Fidler, Isaiah J: 19 articles (02/2008 - 04/2002)|
|5.||Wang, Ping: 18 articles (07/2015 - 06/2006)|
|6.||Nawa, Hiroyuki: 17 articles (01/2014 - 03/2003)|
|7.||Mekada, Eisuke: 16 articles (05/2015 - 09/2002)|
|8.||Miyamoto, Shingo: 16 articles (04/2015 - 07/2005)|
|9.||Yotsumoto, Fusanori: 15 articles (04/2015 - 05/2006)|
|10.||Zhang, Ning: 15 articles (11/2013 - 02/2005)|
04/05/2012 - "Mtss1 positively modulates EGF signaling at low cell densities to promote proliferation and, therefore, may be beneficial for the early stages of primary HNSCC tumor growth. "
02/20/1998 - "(ii) In contrast to earlier findings in tissue homogenates, but consistent with our observation in normal cervical epithelium that cells of the proliferating strata (basal and parabasal cells) express intermediate and comparatively reduced levels of EGFR per cell, cervical cancers displayed a significant reduction both of specific EGF binding and of EGFR levels per cell as compared with normal epithelium. "
01/01/1997 - "EGF binding capacity was significantly greater in metastatic than in nonmetastatic tumors, and in nuclear grade 3 than nuclear grade 1 tumors. "
01/30/2012 - "Fluorescence intensity data from ex vivo imaging showed that the EGF on the nanoparticles helped increase the accumulation of the GemC18-NPs into MDA-MB-468 tumors pre-established in mice by more than 2-fold as compared to the un-targeted GemC18-NPs. "
01/01/2012 - "EGF-NIR imaging of mice with HT-29 orthotopic CRC tumor indicated that EGF-NIR is more slowly cleared from the tumor and the highest SBR between tumor and normal adjacent tissue was achieved two days post-injection. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2014 - "In subgroups of breast cancer, the shortest disease-free and overall survival was observed in basaloid and human epidermal growth factor receptor-2 groups. "
07/01/2015 - "Over the last decade a dramatic improvement in the treatment and prognosis of human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC) has been achieved. "
01/01/2016 - "The present study was undertaken to determine the association of miR-21, smad7, EGF and TGF-β with breast cancer cell invasion and migration and to identify the molecular mechanisms involved using immunohistochemistry and western blot analysis. "
08/01/2014 - "In the present study, we therefore aimed to investigate the influence of MACC1 polymorphisms on event-free and overall survival in patients with human epidermal growth factor 2 (HER2)-positive breast cancer. "
06/01/2014 - "Our aim was to study the effects on breast cancer cell proliferation of EGF, TGFβ and 17β-oestradiol, three important regulators of breast tumourigenesis, and their respective inhibitors in different combinations. "
|3.||Wounds and Injuries (Trauma)
06/01/2006 - "In conclusion, this article demonstrates the efficacy of human recombinant EGF in facilitating re-epithelialisation of partial thickness wounds with the most efficient healing found in EGF concentrations of 1 and 5 ug/g."
11/01/1989 - "Concentrations of EGF greater or less than an optimal dose may be less effective in enhancing corneal wound strength."
08/01/2014 - "The combined treatment with rh-EPO and rh-EGF improved full-thickness wound significantly (P < 0·05) accelerating 50% healing time with higher expression of Ki-67 compared with single growth factor-treated groups. "
09/01/2009 - "Moreover, as a biocompatible equivalent, GG-EGF/TEECM improved the healing of the wound area as indicated by significantly earlier re-epithelialization and dermal maturation. "
06/01/2006 - "The control and the vehicle-only wounds each demonstrated 100% healing time (HT100) of 9.31 +/- 1.34 and 8.5 +/- 1.12 while the wounds treated with EGF ointment with concentrations of 0.1 (HT100 = 6.4 +/- 0.71), 1 (HT100 = 5.2 +/- 0.63), 5 (HT100 = 5.8 +/- 0.85), 10 (HT100 = 7.1 +/- 1.45) and 25 ug/g (HT100 = 7.4 + 0.57) demonstrated significant reduction in time to achieve re-epithelialisation. "
01/01/1994 - "In the clinical trial, the rate of ulcer healing within 8 weeks was 77.9% (67/86) in patients receiving 6 micrograms EGF intravenously twice a week, being significantly greater than 51.7% (45/87) in those given CH. "
01/01/1994 - "These results indicate that EGF is safe and effective in reducing the healing time of herpetic corneal ulcers."
03/01/2000 - "It is concluded that: 1) treatment with TAL activates genes for EGF and its receptor in normal and ulcerated gastric mucosae; 2) since EGF promotes growth of epithelial cells and their proliferation and migration, the above actions of TAL provide the mechanism for its ulcer healing action and improved (versus OME) quality of mucosal restoration."
01/01/2013 - "The aim of our study is to investigate EGF content in biological mediums in children with duodenum ulcer depending on phase of the disease and different variants of its course. "
01/01/1994 - "Subsequent to the clinical study, evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers. "
01/01/2014 - "Nine studies testing the associations between EGF +61 G/A polymorphism and risk of glioma with 1758 cases and 2823 controls were retrieved. "
01/01/2014 - "Extensive studies have found that a single nucleotide polymorphism (SNP) +61 G/A (rs4444903) in the EGF gene is associated with the susceptibility of glioma, however, the results have been controversial. "
06/01/2013 - "To derive a more precise estimation of the association between EGF rs4444903 polymorphism and glioma risk, we performed a systematic review and meta-analysis of previous published studies. "
05/01/2012 - "The purpose of this study was to investigate the potential association between EGF +61G/A and brain glioma in a Chinese population. "
01/01/2012 - "The aim of this study was to perform a meta-analysis of eligible studies to derive precise estimation of the association of EGF +61G/A with glioma risk. "
|1.||Epidermal Growth Factor (EGF)
|2.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|8.||Transforming Growth Factor alpha (TGF-alpha)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Transplantation (Transplant Recipients)